Drezotomía en el tratamiento del dolor por desaferentización: revisión de resultados y análisis de factores predictores de éxito / DREZotomy in the treatment of deafferentation pain: review of results and analysis of predictive factors for success

Antecedentes y objetivos El tratamiento del dolor por desaferentización mediante drezotomía espinal es una opción terapéutica contrastada en la literatura. En los últimos años, la drezotomía ha visto relegado su empleo a un segundo plano debido a la eclosión de las terapias neuromoduladoras. Los objetivos de este estudio son demostrar que la drezotomía continúa siendo un tratamiento efectivo y seguro, y analizar aquellos factores predictores de éxito. Pacientes y métodos Se realizó un estudio retrospectivo de todos los pacientes tratados en nuestro servicio mediante drezotomía espinal desde 1998 hasta 2018. Se excluyeron los casos de drezotomía bulbar. Se emplearon la escala visual analógica (EVA) y la reducción de la medicación habitual como variables resultado, y se analizaron variables demográficas, clínicas y quirúrgicas como factores predictores de éxito. Resultados Un total de 27 pacientes (51,9% mujeres) de 53,7 años de edad media fueron tratados mediante drezotomía. La etiología principal del dolor fue por avulsión de plexo braquial (55,6%) seguida de causa tumoral (18,5%). El tiempo medio de evolución del dolor fue de 8,4 años con una intensidad media de 8,7 según la EVA, pese a que el 63% de los pacientes habían recibido tratamiento neuroestimulador previo. Durante el postoperatorio inmediato un 77,8% de los pacientes presentaron una reducción del 50% o más en la EVA. Tras un seguimiento medio de 22 meses posdrezotomía, permaneció una reducción de al menos el 50% en la EVA en el 59,3% de los pacientes (reducción media de 4,9 puntos) permitiendo una reducción del tratamiento analgésico habitual en el 70,4% de ellos. La drezotomía en la avulsión de plexo braquial presentó una tasa de éxito (93%) superior al resto de patologías (41,7%) de manera significativa (p = 0,001) (AU)

Background and objectives The treatment of deafferentation pain by spinal DREZotomy is a proven therapeutic option in the literature. In recent years, use of DREZotomy has been relegated to second place due to the emergence of neuromodulation therapies. The objectives of this study are to demonstrate that DREZotomy continues to be an effective and safe treatment and to analyse predictive factors for success. Patients and methods A retrospective study was conducted of all patients treated in our department with spinal DREZotomy from 1998 to 2018. Bulbar DREZotomy procedures were excluded. A visual analogue scale (VAS) and the reduction of routine medication were used as outcome variables. Demographic, clinical and operative variables were analysed as predictive factors for success. Results A total of 27 patients (51.9% female) with a mean age of 53.7 years underwent DREZotomy. The main cause of pain was brachial plexus injury (BPI) (55.6%) followed by neoplasms (18.5%). The mean time of pain evolution was 8.4 years with a mean intensity of 8.7 according to the VAS, even though 63% of the patients had previously received neurostimulation therapy. Favourable outcome (≥ 50% pain reduction in the VAS) was observed in 77.8% of patients during the postoperative period and remained in 59.3% of patients after 22 months average follow-up (mean reduction of 4.9 points). This allowed for a reduction in routine analgesic treatment in 70.4% of them. DREZotomy in BPI-related pain presented a significantly higher success rate (93%) than the other pathologies (41.7%) (p = .001). No association was observed between outcome and age, gender, DREZ technique, duration of pain or previous neurostimulation therapies. There were six neurological complications, four post-operative transient neurological deficits and two permanent deficits (AU)

DREZotomy in the treatment of deafferentation pain: review of results and analysis of predictive factors for success. / Drezotomía en el tratamiento del dolor por desaferentización: revisión de resultados y análisis de factores predictores de éxito.

BACKGROUND AND OBJECTIVES: The treatment of deafferentation pain by spinal DREZotomy is a proven therapeutic option in the literature. In recent years, use of DREZotomy has been relegated to second place due to the emergence of neuromodulation therapies. The objectives of this study are to demonstrate that DREZotomy continues to be an effective and safe treatment and to analyse predictive factors for success. PATIENTS AND METHODS: A retrospective study was conducted of all patients treated in our department with spinal DREZotomy from 1998 to 2018. Bulbar DREZotomy procedures were excluded. A visual analogue scale (VAS) and the reduction of routine medication were used as outcome variables. Demographic, clinical and operative variables were analysed as predictive factors for success. RESULTS: A total of 27 patients (51.9% female) with a mean age of 53.7 years underwent DREZotomy. The main cause of pain was brachial plexus injury (BPI) (55.6%) followed by neoplasms (18.5%). The mean time of pain evolution was 8.4 years with a mean intensity of 8.7 according to the VAS, even though 63% of the patients had previously received neurostimulation therapy. Favourable outcome (≥50% pain reduction in the VAS) was observed in 77.8% of patients during the postoperative period and remained in 59.3% of patients after 22 months average follow-up (mean reduction of 4.9 points). This allowed for a reduction in routine analgesic treatment in 70.4% of them. DREZotomy in BPI-related pain presented a significantly higher success rate (93%) than the other pathologies (41.7%) (p=.001). No association was observed between outcome and age, gender, DREZ technique, duration of pain or previous neurostimulation therapies. There were six neurological complications, four post-operative transient neurological deficits and two permanent deficits. CONCLUSION: Dorsal root entry zone surgery is effective and safe for treating patients with deafferentation pain, especially after brachial plexus injury. It can be considered an alternative treatment after failed neurostimulation techniques for pain control. However, its indication should be considered as the first therapeutic option after medical therapy failure due to its good long-term results.

Brain Arteriovenous Malformations: Impact of Neurologic Status, Bleeding, and Type of Treatment on Final Outcome.

BACKGROUND: Well-designed studies assessing the treatment outcome of brain arteriovenous malformations (AVMs) are infrequent and have not consistently included all of the available treatment modalities, making their results not completely generalizable. Moreover, the predictors of poor outcome are not well defined. METHODS: We performed an observational retrospective study of AVM patients. We included patients with clinical, radiologic, and outcome data, with a minimum follow-up of 1 year. Neurologic outcome was documented using the modified Rankin Scale (mRS) at the AVM diagnosis and 30 days after the treatment. RESULTS: There were 117 patients, with equal male/female proportion. The mean follow-up time was 51 months. Treatment distribution in the Spetzler-Martin grades I-III was as follows: 52 (54.6%) surgery, 31 (32.35%) radiosurgery, 2 (0.02%) embolization, and 11 (12%) conservative follow-up. Treatment distribution in Spetzler-Martin grades IV and V was as follows: 4 (20%) surgery, 7 (35%) radiosurgery, and 10 (45%) conservative follow-up. Poor neurologic outcome (mRS ≥ 3) was significantly associated with poor clinical status at diagnosis (Glasgow Coma Scale [GCS] score< 14; odds ratio [OR]: 0.20; 95% confidence interval [CI]: 0.001-0.396; p = 0.010). The rupture of the AVM was associated with poor neurologic outcome. The Lawton-Young Supplementary scale (LYSS) proved to be the most effective in predicting poor outcome. The existence of seizures, treatment-related complications, and conservative treatment was associated with the worsening of the mRS score, whereas the existence of hemorrhage was associated with the likelihood of disability. CONCLUSION: Our results suggest that poor neurologic status at diagnosis, AVM rupture, and conservative treatment were associated with worse outcome. Hemorrhage as initial presentation is related to disability, not with mRS worsening. The LYSS appeared to be the best method to predict outcome.

Bases de la estimulación cerebral profunda / Bases of deep brain stimulation

INTRODUCCIÓN: La estimulación cerebral profunda es una terapia eficaz que está siendo utilizada en un número creciente de indicaciones. Los mecanismos mediante los cuales ejerce efecto terapéutico aún se desconocen en su mayor parte, si bien cada vez se dispone de más datos sobre su influencia en diversos niveles. OBJETIVO: Revisar la bibliografía existente sobre el mecanismo de acción de la estimulación cerebral profunda. Desarrollo. La estimulación cerebral profunda actúa sobre el tejido cerebral estimulado en varios niveles, molecular, celular y de redes neuronales. En su efectividad intervienen factores espaciales, temporales y eléctricos, pero fundamentalmente parece ejercer su función mediante la sustitución de patrones de disparo anómalos, presentes en ciertas enfermedades neurológicas y psiquiátricas. Otros mecanismos, como la neuroprotección o la neurogénesis, permanecen en estudio. CONCLUSIONES: Aunque aún se desconocen muchos efectos por los cuales la estimulación cerebral profunda actúa en el cerebro, parece un tratamiento complejo, con efectos a gran escala, en los que parece primar la corrección de circuitopatías como mecanismo principal

INTRODUCTION: Deep brain stimulation is an effective therapy that is being used in an increasing number of indications. The mechanisms by which it exerts its therapeutic effect are still largely unknown, although there is increasing evidence of its influence at various levels. AIM: To review the existing literature on the mechanism of action of deep brain stimulation. DEVELOPMENT. Deep brain stimulation acts on brain tissue that is stimulated at various levels: molecular, cellular and neural networks. Spatial, temporal and electrical factors are involved in its effectiveness, but it mainly seems to perform its function by replacing anomalous firing patterns, which are present in certain neurological and psychiatric diseases. Other mechanisms, such as neuroprotection or neurogenesis, remain under study. CONCLUSIONS: Although many of the effects by which deep brain stimulation acts on the brain are still unknown, it seems to be a complex treatment, with large-scale effects, in which the correction of circuitopathies seems to prevail as the main mechanism

Estimulación cerebral profunda en la epilepsia farmacorresistente / Deep brain stimulation in drug-resistant epilepsy

INTRODUCCIÓN: La estimulación cerebral profunda (ECP) en la epilepsia farmacorresistente se ha aplicado en varias dianas cerebrales. Sin embargo, su mecanismo de acción no se conoce con exactitud, y la diversidad de dianas hace difícil conocer el grado de evidencia que apoya su utilización. DESARROLLO: Se realiza una revisión bibliográfica sobre la ECP para la epilepsia farmacorresistente. La eficacia de la ECP en la epilepsia farmacorresistente parece mediada por una desincronización de la actividad neuronal en el foco epileptógeno o una modulación de las circuitopatías que existen en la epilepsia, dependiendo de la diana. En la ECP se han utilizado múltiples estructuras corticales y subcorticales, pero solamente la ECP del núcleo anterior del tálamo tiene una evidencia de clase I. CONCLUSIONES: La ECP en la epilepsia es aún objeto de investigación, con evidencia de clase I en la ECP del núcleo anterior del tálamo. El resto de las dianas ha arrojado resultados variables que deben confirmarse con diseños aleatorizados en series de mayor tamaño

INTRODUCTION: Deep brain stimulation (DBS) in drug-resistant epilepsy has been applied to several brain targets. However, its exact mechanism of action is not known, and the diversity of targets makes it difficult to know the degree of evidence that supports its use. DEVELOPMENT: A review of the literature on DBS for drug-resistant epilepsy was conducted. The efficacy of DBS in drug-resistant epilepsy seems to be mediated by a desynchronisation of neuronal activity at the epileptogenic focus or a modulation of the «circuitopathies» that exist in epilepsy, depending on the target. In DBS multiple cortical and subcortical structures have been used, but class I evidence exists only for DBS of the anterior nucleus of the thalamus. CONCLUSIONS: DBS in epilepsy is still under investigation, with class I evidence for DBS of the anterior nucleus of the thalamus. The rest of the targets have yielded variable results that must be confirmed with randomised designs in larger series

Expanded Endoscopic Transclival Approach for Resection of a Chordoid Meningioma without Dural Attachment (MWODA) Located in the Prepontine Cistern.

BACKGROUND: Meningiomas without dural attachment (MWODA) located in the posterior fossa are an unfrequent entity. They are usually located in the fourth ventricle, and their occurrence outside of this anatomic structure is an even more uncommon finding. Chordoid meningiomas are a rare subtype of meningioma, and they have been reported to account for 0.5%-1% of all meningiomas. CASE DESCRIPTION: We report the unusual case of a 36-year-old female patient, with unremarkable past medical history, who presented at our institution complaining of acute binocular diplopia. Right cranial nerve VI paresis was observed on physical examination. Imaging studies revealed an intradural retroclival solid mass that enhanced homogeneously after contrast administration. Interestingly, no dural tail was present. Expanded endonasal endoscopic resection of her retroclival lesion was performed. We used a 4-hand technique with 0 and 30 degrees endoscopes, with intradural pituitary transposition. Gross total resection was achieved and the pathology report described findings consistent with chordoid meningioma. The patient is recurrence-free and in good condition at 1-year follow-up. CONCLUSIONS: We performed a thorough review of the literature, and we found 10 reported cases describing extraventricular MWODA in the posterior fossa. To our knowledge, this is the first reported case of retroclival MWODA with pathologic findings consistent with chordoid meningioma.

Acute subdural hematoma secondary to distal middle cerebral artery aneurysm rupture in a newborn infant.

The authors present the case of a peripheral aneurysmal lesion that developed in a newborn baby and was successfully treated by endovascular parent artery occlusion. Given the natural history of aneurysms, which are prone to rupture and to cause deleterious intracerebral hemorrhage, with high mortality rates, aggressive and early management (endovascular or surgical) is recommended.